home / stock / syre / syre news

SYRE News and Press, Spyre Therapeutics Inc. From 11/04/25

Stock Information
Company Name: Spyre Therapeutics Inc.
Stock Symbol: SYRE
Market: NASDAQ
Website: aegleabio.com
Menu
SYRE SYRE Quote SYRE Short SYRE News SYRE Articles SYRE Message Board
Get SYRE Alerts

News, Short Squeeze, Breakout and More Instantly...
SYRE - Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY basket study of SPY072 evaluating ...
SYRE - Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 + IL-23) and SPY230 (TL1A + IL-23) investigational combination therapies for IBD...

SYRE - Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic disease...

SYRE - Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the t...
SYRE - Spyre Therapeutics prices public offering of 14.8M shares at $18.50 to raise $275M

2025-10-14 02:28:54 ET Spyre Therapeutics ( NASDAQ: SYRE ) announced the pricing of its previously disclosed underwritten public offering, to offer 14,864,865 shares of common stock at a public price of $18.50 per share.... Read the full article on Seeking Alpha ...

SYRE - Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the t...

SYRE - Spyre Therapeutics announces public offering of common stock and pre-funded warrants

2025-10-13 16:12:42 ET More on Spyre Therapeutics Intelligent Development Could Make Spyre Therapeutics Best In Show Seeking Alpha’s Quant Rating on Spyre Therapeutics Historical earnings data for Spyre Therapeutics Financial information for Spyre Ther...
SYRE - Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD...

SYRE - Buy Recommendation Issued On SYRE By Deutsche Bank

2025-09-26 08:15:05 ET Deutsche Bank analyst issues BUY recommendation for SYRE on September 26, 2025 08:34AM ET. SYRE was trading at $15.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy recomme...

SYRE - Intelligent Development Could Make Spyre Therapeutics Best In Show

2025-09-18 22:34:34 ET ... Read the full article on Seeking Alpha For further details see: Intelligent Development Could Make Spyre Therapeutics Best In Show
Previous 10 Next 10